• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.

作者信息

Zheng Mei-Mei, Li Yang-Si, Sun Hao, Wu Yi-Long

机构信息

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China.

出版信息

J Thorac Oncol. 2021 Feb;16(2):e12-e14. doi: 10.1016/j.jtho.2020.10.016.

DOI:10.1016/j.jtho.2020.10.016
PMID:33494928
Abstract
摘要

相似文献

1
Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.奥希替尼引领改善伴有软脑膜转移的EGFR突变型非小细胞肺癌的治疗结果之路。
J Thorac Oncol. 2021 Feb;16(2):e12-e14. doi: 10.1016/j.jtho.2020.10.016.
2
A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.对致编辑信的回应：奥希替尼引领改善伴有软脑膜转移的EGFR突变型非小细胞肺癌的治疗结果之路。
J Thorac Oncol. 2021 Feb;16(2):e14. doi: 10.1016/j.jtho.2020.12.009.
3
Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.奥希替尼用于治疗EGFR突变型非小细胞肺癌的软脑膜疾病
J Thorac Oncol. 2020 Nov;15(11):1705-1708. doi: 10.1016/j.jtho.2020.08.016. Epub 2020 Oct 23.
4
Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.奥希替尼治疗 EGFR 突变型非小细胞肺癌伴 EGFR 酪氨酸激酶抑制剂预处理性脑膜转移的疗效。
Target Oncol. 2018 Aug;13(4):501-507. doi: 10.1007/s11523-018-0581-2.
5
Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.在辅助治疗中，奥希替尼目前不应被视为EGFR突变型非小细胞肺癌的标准治疗方案。
J Thorac Oncol. 2021 Mar;16(3):371-374. doi: 10.1016/j.jtho.2020.12.003.
6
Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation.携带EGFR V843I种系突变的非小细胞肺癌患者对奥希替尼的反应
Lung Cancer. 2020 Dec;150:247-248. doi: 10.1016/j.lungcan.2020.09.019. Epub 2020 Sep 28.
7
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.奥希替尼改善了不论 T790M 突变状态如何的伴有脑膜转移的 EGFR 突变型 NSCLC 患者的总生存期。
J Thorac Oncol. 2020 Nov;15(11):1758-1766. doi: 10.1016/j.jtho.2020.06.018. Epub 2020 Jul 9.
8
Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC.表皮生长因子受体（EGFR）和转染期间重排（RET）联合抑制用于治疗表皮生长因子受体突变的非小细胞肺癌（NSCLC）对奥希替尼的获得性耐药
Ann Pharmacother. 2022 Apr;56(4):503-504. doi: 10.1177/10600280211036909. Epub 2021 Aug 3.
9
Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC.在中国非小细胞肺癌患者中鉴定出一种新型的对奥希替尼敏感的突变，即EGFR H773L。
J Thorac Oncol. 2020 Mar;15(3):e46-e48. doi: 10.1016/j.jtho.2019.11.018.
10
Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.奥希替尼二线及后线治疗 - 突变型非小细胞肺癌患者的真实世界数据。
Future Oncol. 2021 Jul;17(19):2513-2527. doi: 10.2217/fon-2021-0356. Epub 2021 May 14.

引用本文的文献

1
Osimertinib as Salvage Therapy in Advanced Non-Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report.奥希替尼作为奥莫替尼耐药且伴有T790M突变的晚期非小细胞肺癌的挽救治疗：一例报告
Clin Case Rep. 2025 Feb 17;13(2):e70219. doi: 10.1002/ccr3.70219. eCollection 2025 Feb.